{"id":606120,"date":"2026-04-14T11:15:45","date_gmt":"2026-04-14T11:15:45","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/606120\/"},"modified":"2026-04-14T11:15:45","modified_gmt":"2026-04-14T11:15:45","slug":"this-asx-healthcare-stock-is-up-70-in-a-year-and-climbing-again-today","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/606120\/","title":{"rendered":"This ASX healthcare stock is up 70% in a year and climbing again today"},"content":{"rendered":"

After already delivering a standout 12-month run,\u00a0Cogstate Ltd\u00a0(ASX: CGS<\/a>) shares are back in the green on Wednesday.<\/p>\n

The gain follows a quarterly business update that highlighted continued strength in clinical trial contract activity and improving future revenue visibility. <\/p>\n

In afternoon trade, the stock is changing hands at $2.30, up 7.48%.<\/p>\n

That brings the company’s\u00a0market capitalisation<\/a>\u00a0to roughly $393 million and extends its 12-month gain to just over 70%.<\/p>\n

Let’s take a closer look at what was announced. <\/p>\n

\"Happy<\/p>\n

Image source: Getty Images<\/p>\n

Sales contracts keep building in FY26<\/p>\n

According to its\u00a0third-quarter business update<\/a>, Cogstate executed US$25.4 million in sales contracts during the March quarter.<\/p>\n

That brings total sales contracts executed over the first 9 months of FY26 to US$67.1 million. That is well ahead of the US$41.3 million recorded over the same period a year earlier. <\/p>\n

It also marked the company’s strongest March quarter contract result in recent years. The result extends the momentum seen in the first-half as demand broadened across its central nervous system (CNS) trial work.<\/p>\n

Another closely watched metric is contracted future revenue.<\/p>\n

Cogstate said FY26 revenue under contract had risen to US$67.1 million as at 31 March, up from US$53.1 million at 31 December.<\/p>\n

Within that, revenue already locked in for the June quarter increased to US$35.6 million, compared with US$27 million previously.<\/p>\n

Broader trial demand is supporting confidence<\/p>\n

The latest update reinforces the strength of the company’s clinical trials pipeline rather than pointing to a one-off contract win.<\/p>\n

Cogstate’s technology is used by pharmaceutical and biotech groups running CNS-focused trials, including Alzheimer’s disease, mood disorders, sleep conditions, and other neurological programs.<\/p>\n

The business has increasingly benefited from a broader mix of trial work outside Alzheimer’s. Investors appear to favour this because it improves diversification and reduces reliance on any single drug development cycle.<\/p>\n

With the stock still below its 52-week high of $2.97, today’s gain suggests investors are responding to improving revenue visibility.<\/p>\n

Foolish Takeaway<\/p>\n

I believe Cogstate remains a stock worth buying and holding for the long term, particularly as revenue certainty continues improving.<\/p>\n

The steady lift in sales contracts and stronger revenue already locked in for the June quarter both support a more reliable earnings outlook. Broader demand beyond Alzheimer’s also points to a business generating steadier revenue over time, which could be a major win for shareholders.<\/p>\n

After a 70% gain over the past year, the latest update supports the market view that Cogstate’s longer-term growth outlook remains very attractive.<\/p>\n","protected":false},"excerpt":{"rendered":"After already delivering a standout 12-month run,\u00a0Cogstate Ltd\u00a0(ASX: CGS) shares are back in the green on Wednesday. The…\n","protected":false},"author":2,"featured_media":102095,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":{"0":"post-606120","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-au","9":"tag-australia","10":"tag-health","11":"tag-healthcare"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/606120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=606120"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/606120\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/102095"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=606120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=606120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=606120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}